Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.

Abstract

9502 Background: Antiemetic guidelines recommend co-administration of targeted prophylactic medications aimed at inhibiting several molecular pathways involved in emesis. NEPA is a novel, fixed-dos...